BioSpace News Archive

FDA

Bayer’s Prostate Cancer Drug Earns FDA Approval

The U.S. Food and Drug Administration approved Bayer’s Nubeqa (darolutamide) for non-metastatic castration-resistant prostate cancer.

July 31, 2019
·
2 min read
·
Mark Terry
Alligator Plans Phase II Trial of Immunotherapy Compound After Regaining Rights from Janssen

The product was originally licensed in a partnership deal in 2015, which has now been terminated in what is being called a strategic portfolio decision by Janssen.

July 31, 2019
·
2 min read
·
Mark Terry
Bio NC

Cities and Regions Invest in the Life Sciences to Bolster Economic Growth

Many cities, regions and states have an interest in developing the life sciences as being drivers of the economy, creating good-paying jobs both directly and indirectly. Here’s a look at recent news concerning some of these efforts around the country.

July 31, 2019
·
3 min read
·
Mark Terry
Venture Firm Wellington Partners Launches $237 Million Life Science Fund

The fund plans to build a portfolio of about 15 to 20 companies, with a focus on novel biotechnology platforms, new therapeutics and medical devices, as well as diagnostics and digital medicine.

July 31, 2019
·
2 min read
·
Mark Terry
FDA

Merck’s Keytruda Has Been Approved for 20+ Indications, With the Latest Being for Esophageal Cancer

The U.S. Food and Drug Administration approved the anti-PD-1 therapy as a monotherapy for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 with disease progression after one or more previous lines of systemic therapy.

July 31, 2019
·
3 min read
·
Mark Terry
Business

Alexandria Real Estate Equities Plans Another Boston Life Sciences Lab Facility

The site “represents a strategic opportunity to expand Alexandria’s unparalleled, world-class” life science development in the Boston area, said Peter Moglia, co-chief executive officer and co-chief investment officer of Alexandria.

July 31, 2019
·
2 min read
·
Mark Terry
Chamber of Commerce Study Weighs in On HHS’s International Pricing Index Model Policy

Earlier this year, the U.S. Department of Health and Human Services proposed a new policy called the International Pricing Index, which would set specific drug prices based on an international benchmark.

July 31, 2019
·
5 min read
·
Mark Terry
Business

Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer

Arvinas, Inc., a biotechnology company creating a new class of drugs based on targeted protein degradation, announced the appointment of Ronald Peck, M.D. to the newly created position of Chief Medical Officer.

July 31, 2019
·
5 min read
Business

Sensyne Health Signs Collaboration Agreement with Bayer to Accelerate the Development of New Treatments for Cardiovascular Disease using Clinical Artificial Intelligence

First major drug development agreement signed by Sensyne Health since IPO with potential for expansion

July 31, 2019
·
3 min read
Wellington Partners raises EUR 210 million life science fund

Wellington Partners, a leading European venture capital firm investing in early- and growth-stage life science companies, today announced the final close of its fifth-generation fund Wellington Partners Life Science Fund V (WPLS-V).

July 31, 2019
·
4 min read